A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models - Tian, Jing-Hui; Fuhrmann, Steven R.; Kluepfel-Stahl, Stefanie; Carman, Robert J.; Ellingsworth, Larry; Flyer, David C. (Vaccine, 2012)
Keywords: Allergy and Immunology; animal disease models; Animal models; Animals; antibodies; Antibodies, Bacterial - blood; Antitoxins - blood; Bacterial Proteins - genetics; Bacterial Proteins - immunology; Bacterial Toxins - genetics; Bacterial Toxins - immunology; Bacterial Vaccines - administration & dosage; Bacterial Vaccines - genetics; Bacterial Vaccines - immunology; blood serum; Clostridium difficile; Clostridium difficile - genetics; Clostridium difficile - immunology; Clostridium difficile - pathogenicity; Clostridium difficile associated disease; Clostridium Infections - immunology; Clostridium Infections - mortality; Clostridium Infections - pathology; Clostridium Infections - prevention & control; Cricetinae; disease severity; Enterotoxins - genetics; Enterotoxins - immunology; Escherichia coli; Escherichia coli - genetics; Female; Fusion protein; Gene Expression; hamsters; human diseases; humans; immunity; immunization; lethal dose; Mesocricetus; Mice; Mice, Inbred C57BL; neutralization; receptors; recombinant fusion proteins; Recombinant Fusion Proteins - genetics; Recombinant Fusion Proteins - immunology; spores; Survival Analysis; Toxin; toxins; Vaccine; vaccines; Vaccines, Synthetic - administration & dosage; Vaccines, Synthetic - genetics; Vaccines, Synthetic - immunology; C-TAB.G5; PRAS; Toxin; RBD; Clostridium difficile; Clostridium difficile associated disease; ED50; Vaccine; CDAD; Fusion protein; C-TAB; MLD100; minimum 100% lethal dose; pre-reduced anaerobically sterilized; MLD 100; carboxy-terminal toxin A and B; ED 50; 50% effective dose; C-TAB generation 5; receptor binding domains